TMEM88: A Potential Drug Target and Biomarker for Diseases (G92162)

Target Name: TMEM88

NCBI ID: G92162

TMEM88

TMEM88: A Potential Drug Target and Biomarker for Diseases

TMEM88 (TMM88_HUMAN), also known as human T-cell memory-related epitope M88, is a type of protein that is expressed in the human body and is associated with various cellular processes.TMEM88 has been identified as a potential drug target and biomarker for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

TMEM88 is a type of transmembrane protein that is expressed in various tissues throughout the body, including the brain, spinal cord, and blood vessels. It is composed of four extracellular domains: a transmembrane domain, a cytoplasmic domain, a pericellular domain, and a nuclear domain. The transmembrane domain is responsible for the protein's ability to transmit signals across the cell membrane, while the cytoplasmic domain is involved in the protein's localization and stability in the cytoplasm. The pericellular domain is involved in the protein's interactions with other cellular components, and the nuclear domain is responsible for the protein's ability to interact with DNA.

TMEM88 has been shown to play a role in various cellular processes, including cell adhesion, migration, and the regulation of inflammation. It is also involved in the development and progression of several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the most promising aspects of TMEM88 is its potential as a drug target. TMEM88 has been shown to interact with several drug targets, including the and T cell receptor (TLR) signaling pathway, which is involved in the regulation of cellular immune responses. TMEM88 has also been shown to interact with the protein PDGF-R3, which is involved in the regulation of cell growth and differentiation.

In addition to its potential as a drug target, TMEM88 has also been identified as a potential biomarker for several diseases. For example, TMEM88 has been shown to be elevated in the blood of patients with multiple sclerosis, a neurodegenerative disease. It has also been shown to be elevated in the blood of patients with cancer, which may indicate that it is a potential biomarker for this disease.

TMEM88 is also a potential target for new therapies for autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. By targeting TMEM88, researchers may be able to reduce the immune system's response to foreign substances and improve symptoms associated with these disorders.

In conclusion, TMEM88 is a protein that has been identified as a potential drug target and biomarker for several diseases. Its ability to interact with drug targets and participate in the regulation of cellular processes makes it an attractive target for research into new treatments for a variety of conditions. Further research is needed to fully understand the role of TMEM88 in disease and to develop safe and effective therapies that target this protein.

Protein Name: Transmembrane Protein 88

Functions: Inhibits the Wnt/beta-catenin signaling pathway. Crucial for heart development and acts downstream of GATA factors in the pre-cardiac mesoderm to specify lineage commitment of cardiomyocyte development

The "TMEM88 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM88 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets